Over the last decade, Eswatini has made significant progress in the fight against HIV— cutting its rate of new HIV infections in half, according to the SHIMS (Swaziland HIV Incidence Measurement Survey) and SHIMS2 national population-based HIV impact assessment surveys conducted by the Ministry of Health and ICAP. Further progress towards global HIV targets will soon be determined with the SHIMS 3 survey.
ICAP is a longstanding partner of the Ministry of Health in Eswatini, serving as a key technical and implementation partner for projects focusing on the prevention of maternal-to-child transmission (PMTCT), early infant diagnosis, HIV drug resistance surveillance, laboratory improvement, and ongoing training of health care workers, epidemiologists, and researchers.
ICAP In Eswatini
Key Technical Areas
- Capacity building of educational institutions
- HIV prevention, care, and treatment
- Human resources for health
- Laboratory systems strengthening
- Monitoring and evaluation
- Nursing and midwifery
- Population-based surveys
- Prison health
- Prevention of mother-to-child transmission of HIV
- Quality improvement
- Bill & Melinda Gates Foundation
- U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) / U.S. Centers for Disease Control and Prevention (CDC)
- Family Health International 360 National Institutes of Health
- Fleming Fund
Ruben Sahabo, MD
Dr. Ruben Sahabo is the country director for ICAP in Eswatini. Previously, he was the ICAP country director in Rwanda, where he led the rapid expansion of care and treatment activities in Rwanda overseeing technical and financial assistance to over 50 urban and rural clinics that enrolled over 50,000 patients enrolled in HIV care and treatment. He also supported the start-up of ICAP’s programs in Cote d’Ivoire in 2008 and the Democratic Republic of Congo in 2010. Dr. Sahabo has managed numerous program evaluations and research studies in Rwanda and Eswatini and was co-investigator of an evaluation of the Diagnostic Chip for Infectious Diseases in Rwanda, an innovative strategy for an integrated point-of-care microfluidic-based diagnostic device based on “lab on a chip” technologies developed by Columbia University Microscale Bioengineering Laboratory.